These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24314136)

  • 1. In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida.
    Qiao J; Gao P; Jiang X; Fang H
    Ann Clin Microbiol Antimicrob; 2013 Dec; 12():37. PubMed ID: 24314136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ram1 gene, encoding a subunit of farnesyltransferase, contributes to growth, antifungal susceptibility to amphotericin B of Aspergillus fumigatus.
    Qiao J; Song Y; Ling Z; Liu X; Fang H
    Med Mycol; 2017 Nov; 55(8):883-889. PubMed ID: 28159997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan.
    Ikeda F; Saika T; Sato Y; Suzuki M; Hasegawa M; Mikawa T; Kobayashi I; Tsuji A
    Med Mycol; 2009 Mar; 47(2):145-8. PubMed ID: 18668422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-hydroxyisocaproic acid is fungicidal for Candida and Aspergillus species.
    Sakko M; Moore C; Novak-Frazer L; Rautemaa V; Sorsa T; Hietala P; Järvinen A; Bowyer P; Tjäderhane L; Rautemaa R
    Mycoses; 2014 Apr; 57(4):214-21. PubMed ID: 24125484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
    Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
    J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
    Astvad KMT; Hare RK; Arendrup MC
    Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Airway colonisation by Candida and Aspergillus species in Iranian cystic fibrosis patients.
    Nasri E; Fakhim H; Vaezi A; Khalilzadeh S; Ahangarkani F; Laal Kargar M; Abtahian Z; Badali H
    Mycoses; 2019 May; 62(5):434-440. PubMed ID: 30681747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of a new polyene SPK-843 against Candida spp, Cryptococcus neoformans and Aspergillus spp clinical isolates.
    Kantarcioglu AS; Yucel A; Vidotto V
    J Chemother; 2003 Jun; 15(3):296-8. PubMed ID: 12868560
    [No Abstract]   [Full Text] [Related]  

  • 10. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).
    Messer SA; Jones RN; Fritsche TR
    J Clin Microbiol; 2006 May; 44(5):1782-7. PubMed ID: 16672407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal activity of statins against Aspergillus species.
    Qiao J; Kontoyiannis DP; Wan Z; Li R; Liu W
    Med Mycol; 2007 Nov; 45(7):589-93. PubMed ID: 18033614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in
    Espinel-Ingroff A; Turnidge J; Alastruey-Izquierdo A; Botterel F; Canton E; Castro C; Chen YC; Chen Y; Chryssanthou E; Dannaoui E; Garcia-Effron G; Gonzalez GM; Govender NP; Guinea J; Kidd S; Lackner M; Lass-Flörl C; Linares-Sicilia MJ; López-Soria L; Magobo R; Pelaez T; Quindós G; Rodriguez-Iglesia MA; Ruiz MA; Sánchez-Reus F; Sanguinetti M; Shields R; Szweda P; Tortorano A; Wengenack NL; Bramati S; Cavanna C; DeLuca C; Gelmi M; Grancini A; Lombardi G; Meletiadis J; Negri CE; Passera M; Peman J; Prigitano A; Sala E; Tejada M
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal inhibitory concentrations of lucknomycin, a new polyenic derivative, for Candida and Aspergillus spp.
    Martínez-Quesada J; Torres-Rodriguez JM; Rosés-Codinachs M; Amaral-Olivera M
    Antimicrob Agents Chemother; 1983 Jul; 24(1):132-3. PubMed ID: 6625552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii.
    Saribas Z; Yurdakul P; Cetin-Hazirolan G; Arikan-Akdagli S
    Mycoses; 2012 Mar; 55(2):156-60. PubMed ID: 21668525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of a novel compound, Mul-1867, against clinically significant fungi Candida spp. and Aspergillus spp.
    Tetz G; Cynamon M; Hendricks G; Vikina D; Tetz V
    Int J Antimicrob Agents; 2017 Jul; 50(1):47-54. PubMed ID: 28457835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal activity of the essential oil of Thymus pulegioides on Candida, Aspergillus and dermatophyte species.
    Pinto E; Pina-Vaz C; Salgueiro L; Gonçalves MJ; Costa-de-Oliveira S; Cavaleiro C; Palmeira A; Rodrigues A; Martinez-de-Oliveira J
    J Med Microbiol; 2006 Oct; 55(Pt 10):1367-1373. PubMed ID: 17005785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.
    Te Dorsthorst DT; Mouton JW; van den Beukel CJ; van der Lee HA; Meis JF; Verweij PE
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3147-50. PubMed ID: 15273136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2005 Aug; 43(8):3807-10. PubMed ID: 16081915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal activity of the clove essential oil from Syzygium aromaticum on Candida, Aspergillus and dermatophyte species.
    Pinto E; Vale-Silva L; Cavaleiro C; Salgueiro L
    J Med Microbiol; 2009 Nov; 58(Pt 11):1454-1462. PubMed ID: 19589904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.